India, July 8 -- Gurugram-based Premas Biotech, which developed the world's first triple antigen virus-like particle (VLP) vaccine candidate for SARS CoV-2 virus, announces that it has progressed into animal trials. At the moment, it is the only one from India to adopt a triple-antigen approach that is designed to produce an enhanced immune response.

The four-week placebo-controlled, blinded and randomised tests to be conducted in mice, will seek to evaluate safety in the rodent model and examine immune response by dose titration. Premas Biotech plans to administer the test across different dose amounts, including human doses. The company has successfully completed the manufacturing process for the VLP (virus like particle) vaccine candi...